Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Matthews

Showing results (911-920 of 930) with videos related to

Pageof 93
Sort By:
Drug and Alcohol Dependence|June 18, 2017
A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adultsKevin M Gray, Susan C Sonne, Erin A McClure, et al.
American Journal of Respiratory and Critical Care Medicine|May 13, 2022
Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation PhenotypesP Jane McDowell, John Busby, Catherine E Hanratty, et al.
Microbiology Resource Announcements|April 10, 2023
Complete Genome Sequences of Chop, DelRio, and GrandSlam, Three <i>Gordonia</i> Phages Isolated from Soil in Central ArkansasHeidi N Mathes, Elijah I Christenson, John H Crum, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 9, 2023
A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by SexMatthew C Eastwood, John Busby, David J Jackson, et al.
The Lancet. Respiratory Medicine|September 11, 2020
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trialLiam G Heaney, John Busby, Catherine E Hanratty, et al.
Trials|January 6, 2018
A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trialCatherine E Hanratty, John G Matthews, Joseph R Arron, et al.
Journal of Substance Abuse Treatment|March 30, 2020
Documented opioid use disorder and its treatment in primary care patients across six U.S. health systemsDenise M Boudreau, Gwen Lapham, Eric A Johnson, et al.
Open Forum Infectious Diseases|August 11, 2021
Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064)Lisa R Metsch, Daniel J Feaster, Lauren K Gooden, et al.
The Journal of Allergy and Clinical Immunology|June 14, 2023
Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma controlXue Zeng, Jing Qing, Chi-Ming Li, et al.
Thorax|July 25, 2015
Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)Liam G Heaney, Ratko Djukanovic, Ashley Woodcock, et al.
Pageof 93

Showing results (911-920 of 930) with videos related to

Sort By:
Pageof 93
Drug and Alcohol Dependence|June 18, 2017
A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adultsKevin M Gray, Susan C Sonne, Erin A McClure, et al.
American Journal of Respiratory and Critical Care Medicine|May 13, 2022
Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation PhenotypesP Jane McDowell, John Busby, Catherine E Hanratty, et al.
Microbiology Resource Announcements|April 10, 2023
Complete Genome Sequences of Chop, DelRio, and GrandSlam, Three <i>Gordonia</i> Phages Isolated from Soil in Central ArkansasHeidi N Mathes, Elijah I Christenson, John H Crum, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 9, 2023
A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by SexMatthew C Eastwood, John Busby, David J Jackson, et al.
The Lancet. Respiratory Medicine|September 11, 2020
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trialLiam G Heaney, John Busby, Catherine E Hanratty, et al.
Trials|January 6, 2018
A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trialCatherine E Hanratty, John G Matthews, Joseph R Arron, et al.
Journal of Substance Abuse Treatment|March 30, 2020
Documented opioid use disorder and its treatment in primary care patients across six U.S. health systemsDenise M Boudreau, Gwen Lapham, Eric A Johnson, et al.
Open Forum Infectious Diseases|August 11, 2021
Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064)Lisa R Metsch, Daniel J Feaster, Lauren K Gooden, et al.
The Journal of Allergy and Clinical Immunology|June 14, 2023
Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma controlXue Zeng, Jing Qing, Chi-Ming Li, et al.
Thorax|July 25, 2015
Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)Liam G Heaney, Ratko Djukanovic, Ashley Woodcock, et al.
Pageof 93